Hongcheon TwinPig BioLab Selected for 'Scale-up TIPS'... Accelerating Next-Generation ADC Development
Hongcheon County, TwinPig BioLab of the Hongcheon National Antibody Cluster
Selected for the Ministry of SMEs and Startups' "Scale-up TIPS"
Accelerating the Development of Next-Generation Dual-Target ADCs
Hongcheon County in Gangwon Province announced on November 21 that TwinPig BioLab Co., Ltd. (CEO Bae Hyunsoo), a bio new drug development company, has been finally selected for the 'Scale-up TIPS' support program organized by the Ministry of SMEs and Startups.
Aerial view of Hongcheon National Antibody Cluster. Provided by Hongcheon County
View original imageTIPS (Tech Incubator Program for Startup) is a program in which private operators select startups with technological capabilities, provide investment and incubation, while the Ministry of SMEs and Startups supports research and development funding for technological growth. TwinPig BioLab was first selected for TIPS in 2020, then for Post-TIPS in 2024, and now, with its consecutive selection for Scale-up TIPS, it has established itself as a leading deep-tech bio startup in Korea.
TwinPig BioLab has strengthened its technological advancement and global expansion capabilities through support from the 'Gangwon Special Self-Governing Province-Celltrion Open Innovation Program' and Hongcheon County's 'Job-Creating Advanced Industry Promotion Project.' With the Scale-up TIPS project, the company plans to develop and commercialize next-generation antibody-drug conjugates (ADC) globally.
To this end, TwinPig BioLab will fully launch the development of candidate substances that enhance therapeutic effects by improving intracellular drug delivery efficiency over existing treatments using its proprietary technology. At the same time, the company plans to actively pursue joint development and technology transfer collaborations with global pharmaceutical companies.
A TwinPig BioLab representative stated, "Being consecutively selected for TIPS, Post-TIPS, and Scale-up TIPS in all three stages is recognition of our capabilities as an innovative bio startup with both technological prowess and business potential. We will accelerate the development of competitive precision medicines for the global market using domestic technology."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
An official from Hongcheon County said, "We are encouraged by the continued achievements of companies in the Hongcheon National Antibody Cluster, including TwinPig BioLab, in government R&D projects and TIPS selections. We will continue to focus on fostering bio startups with innovative ideas and technological capabilities."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
